Ignite Creation Date:
2025-12-25 @ 2:01 AM
Ignite Modification Date:
2026-02-01 @ 12:44 PM
Study NCT ID:
NCT03544060
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2021-09-16
First Post:
2018-05-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Sponsor:
Akcea Therapeutics
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Familial Chylomicronemia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Familial Chylomicronemia | View |
| None | Familial Lipoprotein Lipase Deficiency | View |
| None | Hyperlipoproteinemias | View |
| None | Familial Hyperlipoproteinemia Type 1 | View |
| None | Hyperlipoproteinemia Type 1 | View |
| None | Hyperchylomicronemia, Familial | View |
| None | Lipoprotein Lipase Deficiency, Familial | View |
| None | Hyperlipidemias | View |
| None | Dyslipidemias | View |
| None | Lipid Metabolism Disorders | View |
| None | Lipid Metabolism, Inborn Errors | View |
| None | Metabolic Diseases | View |
| None | Metabolism, Inborn Errors | View |
| None | Genetic Diseases, Inborn | View |